Intravitreal fluocinolone acetonide 0.19 mg Iluvien implant for radiation maculopathy.

StudyCanadian journal of ophthalmology. Journal canadien d'ophtalmologie· Apr 2026

Intravitreal fluocinolone acetonide 0.19 mg Iluvien implant for radiation maculopathy.

Paul T Finger, Shayri Pillai, Ankit Singh Tomar

Read paper

Ocular OncologyStudyTreatmentQ2IF 1.3

Central foveal thickness decreased 6 months after fluocinolone implant for radiation maculopathy

Intravitreal fluocinolone acetonide 0.19 mg Iluvien implant for radiation maculopathy.

Paul T Finger … Ankit Singh Tomar

Canadian journal of ophthalmology · Apr 2026 · Q2 in Ophthalmology

Purpose

To evaluate the efficacy of a long-acting fluocinolone acetonide 0.19 mg Iluvien intravitreal (FAc) implant for the treatment of radiation maculopathy (radiation maculopathy).

Methods

Seven patients treated for uveal melanoma with palladium-103 plaque brachytherapy who developed radiation maculopathy.

Results

swelling in the retina's center eased, a sign of improved vision

Baseline CFT

390μm

6 months

300μm

Last follow-up

383μm

More results

The median radiation dose to the fovea was 45.9 Gy (mean: 61.8, range: 6.4-135.6).

Radiation maculopathy onset occurred at a median of 12 months post-radiation.

Patients received anti-VEGF therapy for 71 months (mean) before FAc implantation.

More results

A median of 1 (mean: 2, range: 1-3) FAc implant was placed per patient, beginning in 2018.

“

Conclusion · 1 of 2

FAc implants were an effective treatment for radiation maculopathy patients who were refractory or intolerant to maximal intravitreal anti-VEGF therapy.

Conclusion · 2 of 2

They achieved positive results in the stabilization of macular edema and visual acuity, as well as reduced the intravitreal anti-VEGF injection burden for some patients.

Intravitreal fluocinolone acetonide 0.19 mg Iluvien implant for radiation maculopathy.

Intravitreal fluocinolone acetonide 0.19 mg Iluvien implant for radiation maculopathy.

Related papers